DE60112750T2 - Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen - Google Patents

Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen Download PDF

Info

Publication number
DE60112750T2
DE60112750T2 DE60112750T DE60112750T DE60112750T2 DE 60112750 T2 DE60112750 T2 DE 60112750T2 DE 60112750 T DE60112750 T DE 60112750T DE 60112750 T DE60112750 T DE 60112750T DE 60112750 T2 DE60112750 T2 DE 60112750T2
Authority
DE
Germany
Prior art keywords
depression
famotidine
treatment
pharmaceutical composition
ranitidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60112750T
Other languages
German (de)
English (en)
Other versions
DE60112750D1 (de
Inventor
Anna Racz
Peter Kovacs
Csilla Varga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Application granted granted Critical
Publication of DE60112750D1 publication Critical patent/DE60112750D1/de
Publication of DE60112750T2 publication Critical patent/DE60112750T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
DE60112750T 2000-06-06 2001-06-06 Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen Expired - Lifetime DE60112750T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0002154P 2000-06-06
HU0002154A HUP0002154A3 (en) 2000-06-06 2000-06-06 Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
PCT/HU2001/000065 WO2001093863A2 (en) 2000-06-06 2001-06-06 Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression

Publications (2)

Publication Number Publication Date
DE60112750D1 DE60112750D1 (de) 2005-09-22
DE60112750T2 true DE60112750T2 (de) 2006-06-08

Family

ID=89978380

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60112750T Expired - Lifetime DE60112750T2 (de) 2000-06-06 2001-06-06 Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen

Country Status (10)

Country Link
US (1) US20040010021A1 (cg-RX-API-DMAC7.html)
EP (1) EP1289520B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003535133A (cg-RX-API-DMAC7.html)
AT (1) ATE302000T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001266242A1 (cg-RX-API-DMAC7.html)
DE (1) DE60112750T2 (cg-RX-API-DMAC7.html)
DK (1) DK1289520T3 (cg-RX-API-DMAC7.html)
ES (1) ES2247137T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0002154A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001093863A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058296B2 (en) * 2008-11-25 2011-11-15 Richard Tokunaga Treatment and prevention of deleterious effects associated with alcohol consumption
WO2014103801A1 (ja) 2012-12-28 2014-07-03 株式会社新日本科学 イミダゾピリジン誘導体を有効成分として含むoct3活性阻害剤又はoct3検出剤
WO2015002150A1 (ja) 2013-07-03 2015-01-08 株式会社新日本科学 新規化合物,有機カチオントランスポーター3の検出剤及び活性阻害剤
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
IL311338B1 (en) * 2024-03-07 2026-07-01 Ariel Scient Innovations Ltd Using hyaluronic acid to treat mental disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
US5352688A (en) * 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
AU7218294A (en) * 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-alginate combinations
WO1995001784A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-sucralfate-antiflatulent combinations

Also Published As

Publication number Publication date
ES2247137T3 (es) 2006-03-01
WO2001093863A3 (en) 2002-05-02
HU0002154D0 (en) 2000-08-28
ATE302000T1 (de) 2005-09-15
HUP0002154A2 (hu) 2002-04-29
WO2001093863A2 (en) 2001-12-13
AU2001266242A1 (en) 2001-12-17
US20040010021A1 (en) 2004-01-15
EP1289520A2 (en) 2003-03-12
DK1289520T3 (da) 2005-10-17
EP1289520B1 (en) 2005-08-17
HUP0002154A3 (en) 2002-06-28
JP2003535133A (ja) 2003-11-25
DE60112750D1 (de) 2005-09-22

Similar Documents

Publication Publication Date Title
DE60218193T2 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE69231955T2 (de) Verwendung von N-(2,6-Dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamid zur Behandlung von Demenz
DE2523998A1 (de) Pharmazeutische zubereitung fuer die behandlung der schizophrenie
DE69323759T2 (de) Verwendung von toremifene für die behandlung von sle
DE2823174A1 (de) Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose
DE69612510T2 (de) Verwendung von 1-(2-naphtylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
DE69420776T2 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
DE3390116C2 (de) Verbesserte, Koffein enthaltende, analgetische und antiinflammatorische Mittel
DE69605531T2 (de) Carnitinderivat als Arzneimittel zur Behandlung von Arteriosklerose obliterans
DE69131398T2 (de) Verwendung von 5-ht4 rezeptorantagonisten zur behandlung von vorhof-fibrillation und zur vorbeugung von schlaganfall
EP1513533B1 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
DE3916417C2 (cg-RX-API-DMAC7.html)
DE69529819T2 (de) Neue kombination eines betablockers mit einem lokalanästhetikum
DE69907220T2 (de) Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie
DE60120917T2 (de) Kombinationspräparat zur krebstherapie
DE69625210T2 (de) Nicorandil gegen angstneurosen
DE69821970T2 (de) Verwendung von CITICOLINE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
EP1289520B1 (en) Pharmaceutical compositions for the treatment of depression comprising famotidine
DE69129623T2 (de) Behandlungsverfahren für therapiewiderstehende schizophrenie mit amperozide
WO2002007713A2 (de) Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten
DE69904206T2 (de) Verwendung von cetirizin zur vorbeugung von asthma eintritt
EP0820771A2 (de) Arzneimittel zur Behandlung von Neuropathien, das ein lipidlösliches Thiamin und eine Magnesiumverbindung enthält
DE69701139T2 (de) Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität
DE69114261T2 (de) Pharmazeutische zusammensetzungen zur behandlung der parkinson'schen krankheit.
EP2174690A1 (de) Kombinationspräparat mit Cinnarizin und Dimenhydrinat zur Behandlung von Schwindel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition